Liquidia Corporation

LQDAApproved

Liquidia Corporation is a public biopharmaceutical company that utilizes its proprietary PRINT® (Particle Replication In Non-wetting Templates) technology to design, develop, and commercialize precisely engineered particles for the pharmaceutical industry. Its primary focus is on pulmonary arterial hypertension (PAH), with its lead candidate YUTREPIA™ awaiting final FDA approval and commercial launch. The company's platform enables the creation of inhaled, injectable, and oral products with controlled particle size, shape, and composition, aiming to enhance drug performance and patient outcomes.

Market Cap

$3.2B

Employees

100-150

Focus

Biotech

LQDA · Stock Price

USD 36.41+29.38 (+417.92%)

Historical price data

AI Company Overview

Technology Platform

PRINT® (Particle Replication In Non-wetting Templates) is a proprietary particle engineering platform that enables precise design and cGMP production of drug particles with controlled size, shape, and composition for improved therapeutic delivery via inhalation, injection, or oral routes.

Funding History

Total raised: $95M

IPO$40MUndisclosedOct 25, 2018

Series B$35MPappas VenturesJun 15, 2008

Series A$20MNew Enterprise AssociatesJun 15, 2005

FDA Approved Drugs

YUTREPIANDAMay 23, 2025

Opportunities

The primary opportunity is the successful launch of YUTREPIA™, capturing a meaningful share of the multi-billion dollar PAH/PH-ILD therapy market from the current standard of care.

Longer-term opportunities include expanding the PRINT® platform to develop new formulations for other disease areas (oncology, vaccines) and establishing lucrative licensing partnerships with larger pharmaceutical companies.

Risk Factors

The company faces extreme binary risk from ongoing patent litigation with United Therapeutics, which could block YUTREPIA's launch.

Additional risks include commercialization execution, market adoption against a dominant competitor, future capital needs, and high dependence on a single lead product.

Competitive Landscape

Liquidia's main competitor is United Therapeutics (Tyvaso®). YUTREPIA™ aims to compete by offering a more convenient dry-powder inhaler versus Tyvaso's nebulizer. The competitive dynamic is currently defined by legal battles over patents. Liquidia's differentiation is its PRINT® technology, which enables a potentially superior product profile in terms of portability and ease of use.

Publications

FDA Approvals